📊 AZTR Key Takeaways
Is Azitra, Inc. (AZTR) a Good Investment?
Azitra is a pre-revenue pharmaceutical company with zero sales and mounting operating losses (-$3.9M), indicating an unproven business model with high execution risk. While the balance sheet is strong with $10.1M cash and minimal debt providing approximately 4 years of runway at current burn rates, the company remains entirely dependent on R&D success with no commercial products generating revenue.
Azitra remains a pre-revenue biotechnology company with no commercial sales, persistent operating losses, and deeply negative cash generation, indicating that the business has not yet demonstrated economic viability. While the balance sheet is not heavily levered and liquidity is still above 1x, the cash balance of $2.07M appears thin relative to annual operating cash burn of $11.22M, implying substantial financing risk unless fundamentals improve materially.
Azitra, Inc. Key Strengths (AZTR)
- Strong cash position ($10.1M) representing 83% of total assets with zero debt
- Excellent liquidity ratios (6.94x current and quick ratio) providing financial flexibility
- Manageable cash burn rate (~$2.5M annually) relative to cash reserves with improving EPS trend
- Debt-free capital structure reduces financial leverage risk
- Current and quick ratios of 2.83x indicate near-term balance sheet liquidity is still adequate
- Net loss improved year over year, suggesting some operating cost progress
AZTR Stock Risks: Azitra, Inc. Investment Risks
- Zero revenue with no commercial products - completely unproven business model and market viability
- Negative operating cash flow and persistent operating losses worsening year-over-year in absolute terms
- Typical biotech execution risk including dependence on successful clinical trials, regulatory approvals, and market adoption
- Limited financial runway despite cash position - company must achieve commercial success or face depletion
- Zero revenue means the company has not yet proven product commercialization or recurring demand
- Operating cash flow of -$11.22M versus only $2.07M in cash suggests limited runway and likely dependence on external funding
- Returns on equity and assets are extremely negative, reflecting weak capital efficiency and ongoing value erosion
Key Metrics to Watch
- Revenue generation timeline and first commercial product launch date
- Quarterly cash burn rate trend and operating cash flow trajectory
- Clinical trial progress and regulatory milestone announcements
- Cash runway extension through capital raises or partnership announcements
- Quarterly cash burn relative to cash on hand
- Evidence of revenue generation from commercialization, licensing, or collaboration agreements
Azitra, Inc. (AZTR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.94x current ratio provides a solid financial cushion.
AZTR Profit Margin, ROE & Profitability Analysis
AZTR vs Healthcare Sector: How Azitra, Inc. Compares
How Azitra, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Azitra, Inc. Stock Overvalued? AZTR Valuation Analysis 2026
Based on fundamental analysis, Azitra, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Azitra, Inc. Balance Sheet: AZTR Debt, Cash & Liquidity
AZTR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Azitra, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-15.70 indicates the company is currently unprofitable.
AZTR Revenue Growth, EPS Growth & YoY Performance
AZTR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.0M | $-0.67 |
| Q2 2025 | N/A | -$2.6M | $-0.18 |
| Q3 2024 | N/A | -$1.0M | $-0.17 |
| Q2 2024 | $7.5K | -$2.5M | $-2.74 |
| Q1 2024 | N/A | -$2.5M | $-0.15 |
| Q3 2023 | $48.5K | -$1.9M | $-0.16 |
| Q2 2023 | $85.0K | -$1.9M | $-2.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Azitra, Inc. Dividends, Buybacks & Capital Allocation
AZTR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Azitra, Inc. (CIK: 0001701478)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AZTR
What is the AI rating for AZTR?
Azitra, Inc. (AZTR) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AZTR's key strengths?
Claude: Strong cash position ($10.1M) representing 83% of total assets with zero debt. Excellent liquidity ratios (6.94x current and quick ratio) providing financial flexibility. ChatGPT: Debt-free capital structure reduces financial leverage risk. Current and quick ratios of 2.83x indicate near-term balance sheet liquidity is still adequate.
What are the risks of investing in AZTR?
Claude: Zero revenue with no commercial products - completely unproven business model and market viability. Negative operating cash flow and persistent operating losses worsening year-over-year in absolute terms. ChatGPT: Zero revenue means the company has not yet proven product commercialization or recurring demand. Operating cash flow of -$11.22M versus only $2.07M in cash suggests limited runway and likely dependence on external funding.
What is AZTR's revenue and growth?
Azitra, Inc. reported revenue of $0.0.
Does AZTR pay dividends?
Azitra, Inc. does not currently pay dividends.
Where can I find AZTR SEC filings?
Official SEC filings for Azitra, Inc. (CIK: 0001701478) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AZTR's EPS?
Azitra, Inc. has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AZTR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Azitra, Inc. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AZTR stock overvalued or undervalued?
Valuation metrics for AZTR: ROE of -37.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AZTR's AI grade for 2026?
Our dual AI analysis gives Azitra, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AZTR's free cash flow?
Azitra, Inc.'s operating cash flow is $-2.5M, with capital expenditures of $14.9K.
How does AZTR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -37.5% (avg: 15%), current ratio 6.94 (avg: 2).